S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NYSEAMERICAN:HEB

Hemispherx BioPharma (HEB) Stock Price, News & Analysis

$0.47
+0.03 (+6.80%)
(As of 03/28/2024 ET)
Today's Range
$0.45
$0.50
50-Day Range
N/A
52-Week Range
$1.69
$14.81
Volume
422,677 shs
Average Volume
102,599 shs
Market Capitalization
$1.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
HEB stock logo

About Hemispherx BioPharma Stock (NYSEAMERICAN:HEB)

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.

HEB Stock Price History

HEB Stock News Headlines

H-E-B hosting hiring fairs
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Hemispherx's Ampligen Dealt FDA Blow
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
H-E-B plans to hire 700 for its McKinney store
See More Headlines
Receive HEB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hemispherx BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/15/2019
Today
3/28/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:HEB
Fax
N/A
Employees
31
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$1.15 million
Optionable
Not Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Thomas K. Equels (Age 66)
    Exec. Vice Chairman, CEO & Pres
  • Mr. Adam Pascale (Age 71)
    Chief Financial Officer
  • Mr. Peter W. Rodino III (Age 68)
    J.D., Exec. Director of Gov.al Relations, Gen. Counsel & Sec.
  • Mr. Wayne S. Springate (Age 48)
    Sr. VP of Operations
  • Ms. Ellen Lintal
    Chief Accounting Officer

HEB Stock Analysis - Frequently Asked Questions

How were Hemispherx BioPharma's earnings last quarter?

Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) released its quarterly earnings results on Thursday, August, 15th. The specialty pharmaceutical company reported ($1.07) EPS for the quarter, topping the consensus estimate of ($1.70) by $0.63. The specialty pharmaceutical company had revenue of $0.03 million for the quarter.

When did Hemispherx BioPharma's stock split?

Hemispherx BioPharma's stock reverse split on Tuesday, June 11th 2019. The 1-44 reverse split was announced on Friday, May 31st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 10th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Hemispherx BioPharma own?
How do I buy shares of Hemispherx BioPharma?

Shares of HEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:HEB) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners